Skip to main content

Table 1 Baseline characteristics of the study population.

From: Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?

Characteristics Bezafibrate (n = 1506) Placebo (n = 1505) p value
Age (years) 60.0 ± 6.8 60.0 ± 6.7 0.9
Body mass index (kg/m2) 26.7 ± 3.3 26.7 ± 3.3 0.7
Men (%) 1374(91) 1382 (92) 0.6
Past myocardial infarction (%) 1184 (79) 1163 (77) 0.3
Angina (%) 848 (56) 876 (58) 0.3
NYHA Class ≥2 (%) 45 (27) 47 (26) 0.9
Hypertension (%) 462 (31) 507 (34) 0.1
Current smokers 177 (12) 184 (12) 0.7
Systolic blood pressure (mmHg) 134 ± 18 133 ± 18 0.3
Diastolic blood pressure (mmHg) 81.1 ± 9.0 80.8 ± 9.1 0.4
Heart rate (beats/min) 70.1 ± 9.3 70.0 ± 9.3 0.8
Total cholesterol (mg/dl) 211 ± 17 213 ± 18 0.2
HDL-cholesterol (mg/dl) 34.5 ± 5.5 34.6 ± 5.5 0.7
LDL-cholesterol (mg/dl) 148 ± 16 149 ± 16 0.2
Triglycerides (mg/dl) 145 ± 51 145 ± 51 0.9
Fibrinogen (mg/dl) 350 ± 72 351 ± 74 0.7